<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868175</url>
  </required_header>
  <id_info>
    <org_study_id>IIII</org_study_id>
    <nct_id>NCT04868175</nct_id>
  </id_info>
  <brief_title>Interval Intraocular Pressure in Intravitreal Injection Study</brief_title>
  <acronym>IIII</acronym>
  <official_title>The Effects of Topical Beta Blocker and Prostaglandin on Interval Intraocular Pressure in Intravitreal Injection - a Randomised Controlled Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study of IOP in Intravitreal injections to evaluate:&#xD;
&#xD;
        1. IOP effect of intravitreal injection&#xD;
&#xD;
        2. IOP response to prophylactic beta blocker or Prostaglandin vs control (Hypromellose)&#xD;
           over multiple time periods&#xD;
&#xD;
        3. IOP response in correlation to number of injections, IOL, type of anti VEGF, co&#xD;
           morbidities&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: A prospective study Sample size: 60 patients (180 readings) Recruitment:&#xD;
      Patients will be recruited at the intravitreal injection clinic in Grantham Hospital.&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      Group 1: control (hypromellose), then Timolol, then Travatan Group 2: Timolol, then Travatan,&#xD;
      Hypromellose Group 3: Travatan, then Hypromellose, Timolol&#xD;
&#xD;
      There are three groups of different treatments. Patients recruited will undergone all three&#xD;
      groups of treatments. During the first injection visit, patients will be randomized (by&#xD;
      envelope method upon recruitment) to start with one of the three groups by envelope method.&#xD;
      Treatment given to each group according to randomization in the first visit, then rotated to&#xD;
      second and third group at two subsequent injections accordingly.&#xD;
&#xD;
      Injection doctors masked to treatments given.&#xD;
&#xD;
      Study visits:&#xD;
&#xD;
        1. Injection visit&#xD;
&#xD;
             -  Record the anti-VFGF injection to be given&#xD;
&#xD;
             -  Macula disease involved&#xD;
&#xD;
             -  Record no. of previous injections&#xD;
&#xD;
             -  Prophylactic eye drops will be given according to treatment group 1 hour prior&#xD;
                injection&#xD;
&#xD;
             -  IOP immediately before injection (without speculum while sitting on table)&#xD;
&#xD;
             -  IOP immediately after injection (without speculum while sitting on table)&#xD;
&#xD;
             -  IOP 30 minutes after injection via iCare&#xD;
&#xD;
             -  Slitlamp examination, document inflammation or complications if any&#xD;
&#xD;
        2. Day 1 follow-up visit&#xD;
&#xD;
             -  IOP via iCare (sitting)&#xD;
&#xD;
             -  Slitlamp examination, document inflammation or complications if any&#xD;
&#xD;
        3. Week 1 follow-up visit&#xD;
&#xD;
             -  IOP via iCare (sitting)&#xD;
&#xD;
             -  Slitlamp examination, document inflammation or complications if any Visit a, b and&#xD;
                c will be repeated for 2nd and 3rd injections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Group 1: control (hypromellose), then Timolol, then Travatan Group 2: Timolol, then Travatan, Hypromellose Group 3: Travatan, then Hypromellose, Timolol&#xD;
There are three groups of different treatments. Patients recruited will undergone all three groups of treatments. During the first injection visit, patients will be randomized (by envelope method upon recruitment) to start with one of the three groups by envelope method. Treatment given to each group according to randomization in the first visit, then rotated to second and third group at two subsequent injections accordingly.&#xD;
Injection doctors masked to treatments given.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Patients are not exposed to the eye drop bottle (taped) and the doctors measuring pressure and performing the intravitreal injections are not shown the eye drops given</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>IOP effect of prophylactic IOP lowering eye drops over multiple time points</measure>
    <time_frame>From baseline to 30 minutes after injection</time_frame>
    <description>IOP in mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP effect of intravitreal injection</measure>
    <time_frame>From baseline to 30 minutes after injection</time_frame>
    <description>IOP in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP response to types of anti VEGF, IOL, type of anti VEGF and co-morbidities</measure>
    <time_frame>From baseline to 30 minutes after injection</time_frame>
    <description>IOP in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation to types of anti VEGF</measure>
    <time_frame>1 week post injection</time_frame>
    <description>presence of inflammation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Glaucoma</condition>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control (hypromellose), then Timolol, then Travatan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol, then Travatan, Hypromellose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Travatan, then Hypromellose, Timolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol</intervention_name>
    <description>Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travatan</intervention_name>
    <description>Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypromellose</intervention_name>
    <description>Placebo eye drop, lubricant</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AMD patients requiring multiple intravitreal injections (Eylea or Lucentis), not&#xD;
             necessarily 3 month loading.&#xD;
&#xD;
          -  Age &gt;50&#xD;
&#xD;
          -  Chinese patients with ability to read Chinese ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known glaucoma&#xD;
&#xD;
          2. Corneal disease e.g. corneal scarring or opacity preventing fundal view&#xD;
&#xD;
          3. On steroid or anti glaucoma eye drops&#xD;
&#xD;
          4. Prior vitrectomy or glaucoma surgery&#xD;
&#xD;
          5. Recent intraocular surgery i.e. cataracts surgery&#xD;
&#xD;
          6. Pseudophakic with anterior chamber IOL&#xD;
&#xD;
          7. History of ocular inflammatory disease e.g. uveitis&#xD;
&#xD;
          8. Previous laser iridotomy&#xD;
&#xD;
          9. Recent intravitreal injection of steroid&#xD;
&#xD;
         10. Inability for regular follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HKSDS Program</name>
      <address>
        <city>Hong Kong</city>
        <zip>000000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

